A similar trend was observed in patients with lung cancer, as responders to immunotherapy expressed higher ratio levels of CD8A/CSF-1 than non-responders (p=0.052) (online supplemental figure S5G).42 This evidence concerns the gene CD8A and lung carcinoma.